Pharmstandard group of companies. OAO Pharmstandard. Strategic directions of the company's development
About Working at Pharmstandard, aka OTC-pharm.
1. There is no personnel policy as such:
1) They invite and hire people in most cases for those positions in which they do not want and cannot work in the current team. Basically, either complex sections or positions in advance with the prospect of dismissing a person after a certain period of time.
2) Attacks from colleagues are by no means scoundrels and toadies. Talented and bright people, then people with a soft character, and vice versa, too straightforward "fighters for justice." http://nsk.erabota.ru/blogs/articles/5442/
3) This approach further formulates a violation of the law by the company: in terms of the Labor Code of the Russian Federation and the APC of the Russian Federation. In some cases, there are violations on the part of company employees in terms of the Criminal Code of the Russian Federation.
Real situation:
The girl is an employee of the company. HER immediate supervisor regularly calls her to her office and brings her attacks to fainting. Everyone is aware of this incident. They try to hush it up, the person is sent home urgently in an unconscious state. The next day, the person is admitted to the hospital for an indefinite period. Three months later, a person is simply forced to resign from Pharmastandrt. I must say that the girl has 2 young children.
IF you wish this moment is a fact of proceedings for the Prosecutor's Office and the court.
2. The qualifications of employees are very often covered by their loyalty and lack of initiative.
1) Example: In the financial unit, which was led at the time:
Russian Elena, Russian Natalia, Arkhangelskaya Elena.
For a very long time, they made a report in which net profit was increased by income tax. Well, other such serious blunders.
At the same time, when you show their mistakes, they start to get mad and react inadequately to their own incompetence.
2) Employees eagerly spend much time in the place of the main functionality for behind-the-scenes games. Therefore, there is no question of any efficiency of the company with this approach.
3. Social responsibility of the company and its management.
Do not hesitate to rummage through the personal belongings of colleagues at work. Somehow, returning from lunch, I was surprised by the fact that my personal belongings - my colleague, Makarov Dmitry Yuryevich, is rummaging through my bag. At the same time, there are cameras all around, everything is viewed and recorded. This is an article of the Criminal Code of the Russian Federation.
The company itself denies any cuts. In 2013, family employees were the first to be laid off. employees with children.
4. Being in an advanced industry, the company practically does not spend on research, preferring to vacuum the market by buying up developments from the Soviet period.
In summary, I can say:
- the backbone of the company is satisfied with the current income and they do not see the point in working.
- many go to work to play psychological games, instead of the basis of the work. To the point of interfering with the personal life of an employee.
- the staff of the company strongly supports the current situation.
- mass violations of the law.
- reduction of payment of income on far-fetched pretexts.
- an outdated product line.
- the use of a semi-monopoly position in the market, instead of real work.
(ISIC : 21)
Production capacity
The total production capacity allows the company to produce more than 1.7 billion packages per year. The production facilities of the Pharmstandard group of companies are provided by 9 factories for the production of medicines:
- Russia Russia: Kursk, Pharmstandard-Leksredstva JSC
- Russia Russia: Ufa , JSC Pharmstandard-UfaVITA
- Russia Russia: Tomsk , JSC "Pharmstandard-Tomskhimfarm"
- Russia Russia: Moscow region, JSC "Biomed" them. I. I. Mechnikova
- Russia Russia Location: Moscow, PHARMAPARK LLC
- Russia Russia: Vladimir region, CJSC "Lekko"
- Russia Russia: Tyumen , JSC "TZMOI"
- Ukraine Ukraine: Kharkiv , Pharmstandard-Biolek PJSC
- Singapore Singapore: Bever Pharmaceutical PTE Ltd
Story
Pharmstandard was founded in 2003 by Profit House (a Millhouse Capital structure that managed Roman Abramovich's assets). By that time, the company owned only two Russian pharmaceutical plants: Fitopharm-NN in Nizhny Novgorod and Ufavita in Ufa. Five more were purchased from the American pharmaceutical giant ICN Pharmaceuticals: October in St. Petersburg, Marbiopharm in Yoshkar-Ola, Leksredstva in Kursk, Polifarm in Chelyabinsk and Tomskhimfarm in Tomsk.
Subsequently, three plants were sold or closed for various reasons: Oktyabr (inconveniently located in the very center of the city), Marbiopharm (focused on the production of substances secondary to the Pharmstandard strategy), Polipharm (required too much investment).
In 2005, Pharmstandard bought the Tyumen Plant of Medical Equipment and Instruments.
By 2006 to bring production to compliance international standards quality GMP company has spent more than $70 million.
In 2006, Pharmstandard bought Masterlek, which had 15 well-known brands in its assets. In particular, the rights to Arbidol, Amiksin and Flukostat were obtained. By that time, the holding's production capacity exceeded 1 billion packs per year, and all forms of medicines (tablets, suspensions, capsules, sprays) were produced at the Pharmstandard factories. By the end of the year, Arbidol came out on top in sales in Russia, pushing hawthorn tincture aside.
In 2006, the company launched several more high-tech drugs into production: the first growth hormone in Russia, Rastan, developed at the Institute of Bioorganic Chemistry, and genetically engineered human insulin Biosulin. At the moment Pharmstandard is the largest Russian manufacturer of insulin. The company's capacity would be enough to meet 100% of the needs of Russians in this drug, but so far Russia imports most of the insulin from abroad.
Since 2007, Pharmstandard has been actively working with foreign partners: for example, at Tomskhimfarm, together with Solvay Pharma (France), the production of drugs IRS19 and Imudon has begun.
In 2008, Pharmstandard entered into an agreement with the Latvian enterprise "Grindeks" (Latvia) for the exclusive distribution and promotion of the drug Mildronate, is mastering the production of Afobazole, and is introducing the genetically engineered drug Neypomax into production.
In 2009, Pharmstandard became the first and currently the only Russian member of the International Council of Producers, Distributors and Consumers of Active Pharmaceutical Ingredients (Excipients) in Europe (IPEC Europe). In the same year, the company implemented an operation to introduce a specialized IP solution for the central office and factories.
In 2009, Pharmstandard became the first Russian full member of the International Pharmaceutical Excipients Council Europe (IPEC Europe) International Council of Manufacturers, Distributors and Consumers of Active Pharmaceutical Ingredients (Excipients) in Europe.
In 2010 year State Corporation Rostec and OJSC Pharmstandard signed a cooperation agreement.
In 2010, Pharmstandard announces the acquisition of 100% of the shares of CJSC Vindexpharm.
In 2011, Pharmstandard announces the acquisition of a 55% stake in Biolek PJSC (Ukraine).
In 2011, Pharmstandard was recognized as the most influential Russian pharmaceutical manufacturer.
In 2012, Pharmstandard OJSC announces that Pharmstandard-UfaVITA OJSC and Pharmstandard-Leksredstva OJSC have joined the Association of Pharmaceutical Manufacturers of the Eurasian Economic Community.
In 2012, Pharmstandard OJSC acquired 50.1% of Bigpearl Trading Ltd. and 100% ZAO LEKKO. The amount of investments did not exceed $80 million.
In 2013, Pharmstandard OJSC bought 100% of Singapore's Bever pharmaceutical PTE Ltd for $590 million.
In 2018, Pharmstandard OJSC becomes the 100% owner of the PET-technology network of nuclear medicine centers, having bought the remaining 49.9% from Rosnano. The deal amounted to 2.9 billion rubles.
In August 2018, Pharmstandard entered into an agreement with the American biopharmaceutical company Gilead (Gilead Sciences) on the production of Sovaldi (Sofosbuvir) for the treatment of chronic hepatitis C and Truvada (Tenofovir/emtricitabine) for the treatment of HIV at Pharmstandard's facilities.
Owners and management
CEO- Grigory Potapov. Chairman of the Board of Directors - Viktor Kharitonin.
The main owner of the company is Augment Investments Ltd (54.32%, owned by Viktor Kharitonin and Yegor Kulkov), 9.68% of the shares are traded on the MICEX and RTS, 27.56% in the form of GDRs - on the London Stock Exchange. In March 2008, Roman Abramovich, Evgeny Shvidler and Millhouse Capital Management, who previously owned large stakes in the company, withdrew from its capital.
Primary placement
On May 4, 2007, during an Initial Public Offering (IPO), the company placed its shares in the Russian Trading System (RTS) and Global Depository Receipts (GDR) on the London Stock Exchange (LSE). Investors showed interest in the company's shares, and the placement passed at the upper limit of the established range - $58.2 per share and $14.55 per depositary receipt. The capitalization of the company following the results of the IPO amounted to $2.2 billion.
Pharmstandard placed 40% of its authorized capital on the Russian and London stock exchanges, raising $880 million before the option is exercised. Citi and UBS Investment Bank became global co-coordinators of the placement.
Pharmstandard is the first Russian pharmaceutical company whose shares are listed on the international market.
Activity
By the beginning of 2013, Pharmstandard owned seven pharmaceutical plants and one plant for the production of medical equipment and instruments. The company's factories produce more than 250 types of drugs (more than 120 items are included in the List of Essential Drugs (VED)). The company's capacity is more than 1.7 billion packages per year.
Pentalgin tablet
- "Pharmstandard-Ufavita" in Ufa. The factory was founded in 1916. General Director - Vladimir Kreyman. The number of employees is 1400 people. Main brands: Complivit, Biosulin, Rastan, Neypomax, Phosphogliv.
- "Pharmstandard-Fitofarm-NN" in Nizhny Novgorod
- "Pharmstandard-Tomskhimfarm" in Tomsk. The factory was founded in 1913. General Director - Andrey Skorokhod. The number of employees is over 600 people. Main brands: Arbidol, Amiksin, Imudon, Thermikon, IRS-19.
- "Pharmstandard-Leksredstva" in Kursk. The factory was founded in 1922. General Director - Eugene Prokhoda. The number of employees is over 1450 people. Main brands: Arbidol, Pentalgin, Phosphogliv.
- Tyumen plant of medical equipment and instruments. The plant was founded in 1962. General Director - Alexander Nizovtsev. The main specialization of the plant is single-use medical products (needles, syringes, droppers, catheters, urinals), sterilization equipment (steam sterilizers), water distillers, water collectors.
The Pharmstandard group of companies produces more than 250 types of drugs, including drugs for the treatment of cardiovascular diseases, diabetes, growth hormone deficiency, gastroenterological, neurological, infectious diseases, metabolic disorders, oncological and other diseases.
Performance indicators
- 2013 - 55.92 billion rubles. (growth compared to 2012 by 8.8%);
- 2012 - 51.391 billion rubles (growth compared to 2011 by 20.5%);
- 2011 - 42.653 billion rubles. (growth compared to 2010 by 43.7%);
- 2010 - 29.694 billion rubles. (growth compared to 2009 by 23.2%);
- 2009 - 24.096 billion rubles. (growth compared to 2008 by 68.1%).
Net profit in different years was:
- 2012 - 9.96 billion rubles. (growth by 12.8%);
- 2011 - 8.832 billion rubles. (growth by 23.3%);
- 2010 - 7.163 billion rubles. (growth by 4.5%);
- 2009 - 6.852 billion rubles. (growth by 96%).
Export
Pharmstandard exports products to 16 countries:
The strategic plans include the expansion and development of business in:
- Venezuela, Argentina, Nicaragua, Nigeria, Egypt, Iran, Iraq, Afghanistan, UAE.
According to the results of 2012, the export sales of the company's pharmaceutical products increased by 41.1% and amounted to 1,320.9 million rubles compared to 935.9 million rubles in 2011.
Awards and ratings
The drug Arbidol, which is included in the company's portfolio, took the 1st line in terms of sales in 2007 on Russian market over-the-counter drugs
: PHST , RTS : PHST , MICEX: PHST
Russia: Dolgoprudny, Moscow Oblast
Viktor Kharitonin (Chairman of the Board of Directors), Igor Krylov (CEO)
▲ RUB 42.66 billion (2011, IFRS)
▲ RUB 8.83 billion (2011, IFRS)
Story
Pharmstandard was founded in 2003 by Profit House (a Millhouse Capital structure that managed Roman Abramovich's assets). By that time, the company owned only two Russian pharmaceutical plants: Fitopharm-NN in Nizhny Novgorod and Ufavita in Ufa. Five more were purchased from the American pharmaceutical giant ICN Pharmaceuticals: Oktyabr in St. Petersburg, Marbiopharm in Yoshkar-Ola, Leksredstva in Kursk, Polifarm in Chelyabinsk and Tomskhimfarm in Tomsk.
Subsequently, three plants were sold or closed for various reasons: Oktyabr (inconveniently located in the very center of the city), Marbiopharm (focused on the production of substances secondary to the Pharmstandard strategy), Polipharm (required too much investment).
In 2005, Pharmstandard bought the Tyumen Plant of Medical Equipment and Instruments.
By 2006, the company spent more than $70 million to bring production in line with international GMP quality standards.
In 2006, Pharmstandard bought Masterlek, which had 15 well-known brands in its assets. In particular, the rights to Arbidol, Amiksin and Flukostat were obtained. By that time, the holding's production capacity exceeded 1 billion packs per year, and all forms of medicines (tablets, suspensions, capsules, sprays) were produced at the Pharmstandard factories. By the end of the year, Arbidol came out on top in sales in Russia, overtaking Viagra and hawthorn tincture.
In 2006, the company launched several more high-tech drugs: the first growth hormone in Russia, Rastan, developed at the Institute of Bioorganic Chemistry, and genetically engineered human insulin Biosulin. At the moment Pharmstandard is the largest Russian manufacturer of insulin. The company's capacity would be enough to meet 100% of the needs of Russians in this drug, but so far Russia imports most of the insulin from abroad.
Since 2007, Pharmstandard has been actively working with foreign partners: for example, at Tomskhimfarm, together with Solvay Pharma (France), the production of IRS19 and Imudon drugs has begun.
In 2008, Pharmstandard entered into an agreement with the Latvian enterprise Grindeks (Latvia) for the exclusive distribution and promotion of the drug Mildronate, mastering the production of Afobazol, and introducing the genetically engineered drug Neipomax into production.
In 2009, Pharmstandard became the first and currently the only Russian member of the International Council of Producers, Distributors and Consumers of Active Pharmaceutical Ingredients (Excipients) in Europe (IPEC Europe). In the same year, the company implemented an operation to introduce a specialized IP solution for the central office and factories.
Owners and management
The main owner of the company is Augment Investments Ltd (57%, owned by Viktor Kharitonin and Yegor Kulkov), 18% of the shares are traded on the MICEX and RTS, 25% in the form of GDRs on the London Stock Exchange. In March 2008, Roman Abramovich, Evgeny Shvidler and Millhouse Capital Management, who previously owned large stakes in the company, withdrew from its capital.
Primary placement
On May 4, 2007, during an Initial Public Offering (IPO), the company placed its shares in the Russian Trading System (RTS) and Global Depository Receipts (GDR) on the London Stock Exchange (LSE). Investors showed interest in the company's shares, and the placement passed at the upper limit of the established range - $58.2 per share and $14.55 per depositary receipt. The capitalization of the company following the results of the IPO amounted to $2.2 billion.
Pharmstandard placed 40% of its authorized capital on the Russian and London stock exchanges, raising $880 million before the option is exercised. Citi and UBS Investment Bank became global co-coordinators of the placement.
Pharmstandard is the first Russian pharmaceutical company whose shares are listed on the international market.
Activity
By the beginning of 2010, Pharmstandard owned four pharmaceutical plants and one plant for the production of medical equipment and instruments. The company's factories produce more than 240 types of drugs (about 90 items are included in the List of Essential Drugs (VED)). The company's capacity is more than 1.3 billion packages per year.
Pentalgin tablet
- "Pharmstandard-Ufavita" in Ufa. The factory was founded in 1916. General Director - Vladimir Kreyman. The number of employees is 1400 people. Main brands: Complivit, Biosulin, Rastan, Neypomax, Phosphogliv.
- "Pharmstandard-Fitopharm-NN" in Nizhny Novgorod
- "Pharmstandard-Tomskhimfarm" in Tomsk. The factory was founded in 1913. General Director - Pavel Smachkov. The number of employees is over 600 people. Main brands: "Arbidol", "Amiksin", "Imudon", "Termikon", "IRS-19".
- "Pharmstandard-Leksredstva" in Kursk. The factory was founded in 1922. General Director - Eugene Prokhoda. The number of employees is over 1450 people. Main brands: Arbidol, Pentalgin, Phosphogliv.
- Tyumen plant of medical equipment and instruments. The plant was founded in 1962. General Director - Alexander Nizovtsev. The main specialization of the plant is single-use medical products (needles, syringes, droppers, catheters, urinals), sterilization equipment (steam sterilizers), water distillers, water collectors.
Performance indicators
The company's revenue in 2007 amounted to 11.3 billion rubles. (in 2006 - 8.5 billion rubles, an increase of 22%), net profit - 3.2 billion rubles. (2 billion rubles)
Registration number: LS-002525-060314
Trade name of the drug: Piperazine
INN: piperazine adipate
Chemical Name: hexahydropyrazine adipate
Dosage form: tablets
Composition per tablet
Active substance: piperazine adipate - 0.5 g;
Excipients: potato starch - 0.077 g, talc - 0.018 g, gelatin (medical gelatin) - 0.005 g.
Description. Tablets of white color, ploskotsilindrichesky form, with a facet and risk.
Pharmacotherapeutic group: anthelmintic agent.
ATX code: .
Pharmacological properties
Pharmacodynamics
It has a paralyzing effect on nematodes (roundworms, pinworms), disrupting the function of their neuromuscular system, causing muscle paralysis. The severity of deworming with the drug is at the level of 90-95%, and with repeated use it can be about 100%. Due to the fact that piperazine does not destroy ascaris, there is no danger of absorption of biological toxic products of their decay. The drug has low toxicity.
Pharmacokinetics
The drug is rapidly absorbed from the gastrointestinal tract. It is excreted from the body mainly by the kidneys.
Indications for use: ascariasis and enterobiasis.
Dosage and administration
inside. In the treatment of ascariasis, the drug is prescribed for two consecutive days 2 times a day 1 hour before or 0.5-1 hour after meals in the following doses: adults and children from 15 years old - 1.5 g - 2.0 g; children aged 3 to 5 years - 0.5 g (daily dose 1.0 g), from 5 to 8 years - 0.75 g (daily dose 1.5 g), from 8 to 12 years - 1.0 g (daily dose 2.0 g), from 13 to 15 years old - 1.5 g (daily dose 3.0 g), it is possible to use the drug for one day once at a dose of 0.5 g to 4.0 g, depending from age.
The maximum daily dose in adults is 4.0 g.
With enterobiasis in the same doses, the drug is prescribed for 5 consecutive days (perform 1-3 courses of therapy with a 7-day break between courses) or within one day once at a dose of 0.5 g to 4.0 g, depending on age In the intervals between cycles, an enema is prescribed at night to mechanically wash out the pinworms (adults 4-5 glasses of water, children 1-2 glasses with the addition of 1/2 teaspoon of sodium bicarbonate to a glass of water).
Side effect
Rarely nausea, abdominal pain, headache which quickly disappear. In patients with renal insufficiency, neurotoxic complications (muscle weakness, tremor, euphoria, hallucinations, blurred vision, impaired coordination of movements) can be observed.
Contraindications
Organic diseases of the central nervous system. Hypersensitivity. Chronic renal failure, pregnancy and lactation. Childhood up to 3 years (for this dosage).
Overdose
In case of overdose, unexpressed muscle weakness, tremor, neurotoxic phenomena are observed, especially in patients with impaired renal excretory function. Overdose assistance measures: removal of the drug from the stomach and intestines (gastric lavage, artificial vomiting, the use of saline laxatives, enema, the use of intestinal adsorbents - activated carbon), symptomatic treatment. If necessary, carry out oxygen and transfusion therapy. With neurological symptoms, thiamine is administered.
special instructions
Preliminary preparation of patients is not required. During the treatment, strict adherence to the hygienic regimen is necessary. Laxatives are prescribed only for patients with a tendency to constipation in the evening (on the days of taking piperazine). The safety of the drug during pregnancy and lactation has not been established.
Influence on the ability to drive vehicles, mechanisms
The drug does not affect the ability to manage vehicles and various mechanisms, as well as other potentially hazardous activities that require increased attention and speed of mental and motor reactions.
Interaction with other drugs
Enhances the severity of extrapyramidal disorders caused by chlorpromazine.
RELEASE FORM
Tablets 0.5 g.
10 or 20 tablets in a blister pack. 10 tablets in a blister pack.
30, 50 or 100 tablets in a polymer jar.
1, 2, 3 or 5 contour packs or a polymer jar, together with instructions for use, are placed in a pack.
It is allowed to place blisters or non-cell packs with an equal number of instructions for use in a group package.
Best before date 5 years. After the expiration date, the drug should not be used.
Storage conditions
Store at a temperature not exceeding 25 °C.
Keep out of the reach of children.
The holding is huge and heterogeneous, as luck would have it. For some, luck is to kick the bullshit, for someone - to develop and work in a good team. There are departments for both the first and the second. In the "fields" is also different. Do not judge by hrs, they are strange here)
There are a huge number of characters with self-conceit of the universal scale and negative efficiency. And the budget for their maintenance is a kind of charity in favor of mentally disabled people.
07.11.19 18:14 Moscow cityEmployee,
Office next to the subway.
The vacancy of an analyst is updated from time to time, it hangs constantly. At the interview, it is positioned that analysts have been working here for a long time. This is very pathetically stated by the head of the department. A stupid mindfulness test for third graders. Lack of feedback.
01.10.19 13:48 in the Moscow regionCoca Cola,
a good VMI, if you do not take into account dentistry, according to which you can only do an ultrasound cleaning of your teeth once a year, a white salary on a VTB card or Sberbank, that's all
gossip and blather. if you came on an ad, you can’t even dream of any career growth. I will separately tell you about the position of "Project Administrator" with Comrade Zyryanov I.B. If you value yourself even a little bit, run away from here, I'm serious. At the interview, everyone colorfully tells: what a wonderful team in IT (lies, everyone follows each other and knocks on Zyryanov to ...
21.03.19 11:48 Moscow cityLelya Krok,
Nice office
This was the first place I was asked when I was going to have my third child. And I had a lot of interviews. It was tempting to ask if they were asking these kinds of questions to men. In addition, they have 3 or 4 rounds of interviews. At the same time, the vacancy has been hanging for exactly more than six months. They talked down (basically, the head of the department, HR is still nothing). They tortured me for a long time about my life path ...
26.10.18 22:15Moscow cityBuyer,
26.10.18 22:13Moscow cityBuyer,
Feedback from the buyer. Medicines are mostly fake. Mukaltin, well, what the hell, it won't do anyone any good or harm either. Pure soda tablets. That Mukaltin, which we are treated for cough and does not smell. They sell just pressed soda. Tip: do not buy drugs from this company! It's empty!
13.09.18 15:43 in the Moscow regionformer employee,
A stable company, salary is not delayed, there are bonuses, medical insurance is normal, especially for managerial positions, corporate parties, a canteen, sometimes they can even be sent to study for courses (rarely). A great opportunity for growth - unless of course you came not from the street, but a relative or friend of someone from the leadership. The director at Pharmstandard LLC Darko Y. is smart, knowledgeable and decent, it’s a pity that there are two deputies for them, ...
If you are an ordinary employee, there is little good, especially in the procurement department of an LLC, there are two deputies Mashnikova and Strigulin. authoritarian communication style. If you are a decent person and a professional, it will be difficult for you here, because. you have to show a lot of devotion...
05.02.18 16:21 Moscow cityMasha Anastasia,
I worked for over half a year. Leadership: Podgorbunskikh N.I., Usmanova E. and Mr. Tolstova - completely inadequate. They do not know what they want from employees, they are rude, bring to tears. They took on one position, the duties were completely different. Sneaky surveillance of people, a report on the work every day about your every step (when you went to the toilet, ate, sat on the Internet) Low and disgusting, and this, for a minute ...